• Events
  • Expert meeting: Foundation Team in India for AMR discussions...
Expert meeting - Event date: 12 Mar 2018

Foundation Team in India for AMR discussions with key stakeholders

From 12 to 16 March, the Access to Medicine Foundation will be visiting New Delhi and Mumbai, India, for a series of meetings with government representatives and Indian pharmaceutical companies that are already actively addressing antimicrobial resistance (AMR). The objective is to identify concrete opportunities for adapting business practices to match current best practice for controlling AMR: in the areas of R&D and incremental innovation, responsible manufacturing, and appropriate antibiotic promotion and access.

On Wednesday, 13 March, Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, will participate in the Delhi End TB Summit “Innovations and Changed Mindsets to End TB” that will take place in New Delhi. The event, organised by the Government of India, the Stop TB Partnership and World Health Organization (WHO), will bring together national governments, global health experts and multilateral institutions to discuss TB and their concerted actions to end it. The keynote speech at the opening session will be delivered by His Excellency Narendra Modi, Prime Minister of India, who will also launch the “India TB Elimination Campaign” at the event. On Thursday, 14 March, Jayasree will join a private sector session, which is part of the Stop TB Partnership’s 30th Board Meeting in New Delhi, to discuss TB and pharmaceutical company actions to curb AMR.

These discussions will be followed by bilateral meetings with pharmaceutical companies evaluated in the AMR Benchmark in Mumbai. The Foundation team will share the results of the Benchmark and highlight existing opportunities for Indian manufacturers to ensure a reliable supply of high-quality antibiotics that are manufactured and used responsibly. Read more in our new briefing paper “How action in India can have global impact: The Indian pharmaceutical industry and antimicrobial resistance.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |